Pfizer, which spent much of last year trying to acquire U.K. giant AstraZeneca, is now sitting on about $33 billion in cash, and the company’s deal pedigree has analysts dreaming of major M&A down the line.

…read more

Source: Pfizer has $33B and the M&A world at its feet


0 No comments